Noninvasive Stimulation for Spinal Cord Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how a non-invasive method called transcutaneous spinal cord stimulation (TSCS) can help people regain certain body functions after a spinal cord injury. It aims to improve bladder, bowel, sexual, and heart functions, reduce muscle tightness, and ultimately enhance quality of life. Participants will be divided into two groups: one will receive real stimulation, and the other will receive a placebo before both eventually receive the real treatment. The trial is suitable for individuals who have had a spinal cord injury for 3 to 6 months and experience bladder function issues.
As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could significantly enhance recovery options for spinal cord injury patients.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications, but you must notify the Principal Investigator if you start any new medications for bowel and lower urinary tract management during the study.
What prior data suggests that this non-invasive transcutaneous spinal cord stimulation is safe for individuals with spinal cord injury?
Research has shown that transcutaneous spinal cord stimulation (TSCS) is generally safe for people with spinal cord injuries. Studies indicate that combining TSCS with activity-based therapy can be effective without causing major side effects. In previous studies, participants did not report serious problems, suggesting that the treatment is well-tolerated. Another study found that TSCS is safe to use at home or in a clinic to help improve strength and function. These findings support the safety of TSCS for people considering this trial.12345
Why are researchers excited about this trial?
Researchers are excited about spinal cord neuromodulation for spinal cord injury because it offers a noninvasive approach that could sidestep the need for surgery. Unlike traditional treatments, which often involve medication or invasive procedures, this method uses transcutaneous spinal cord stimulation (TSCS) to target specific spinal segments from outside the body. By delivering electrical stimulation through the skin, it potentially enhances nerve function and recovery without the risks associated with surgery. This innovative approach could provide a safer, more accessible option for improving mobility and quality of life in individuals with spinal cord injuries.
What evidence suggests that non-invasive transcutaneous spinal cord stimulation is effective for spinal cord injury?
Research has shown that transcutaneous spinal cord stimulation (TSCS) may aid recovery from spinal cord injuries. In this trial, participants in Group 1 will receive TSCS at or between cervical spinal segment 5 (C5) and thoracic spinal segment 10 (T10). Studies have found that combining TSCS with physical therapy can enhance movement and leg function. Specifically, one study showed that patients experienced better motor skills and improved walking ability after using TSCS with robotic training. Another report noted that repeated TSCS sessions aided overall recovery. These findings suggest that TSCS could also improve bladder, bowel, sexual, and heart functions, and reduce muscle stiffness (spasticity) for those with spinal cord injuries.26789
Who Is on the Research Team?
Andrei Krassioukov, MD,PhD,FRCPC
Principal Investigator
The University of British Columbia, International Collaboration on Repair Discoveries (ICORD)
Are You a Good Fit for This Trial?
This trial is for adults with recent spinal cord injuries (3-6 months ago) who are experiencing issues with bladder, bowel, sexual function, or muscle spasms. It's taking place in Canada and Ukraine. Participants will join a study lasting about 33 weeks to see if non-invasive spine stimulation helps improve these functions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase 1
Group 1 receives therapeutic TSCS and Group 2 receives sham stimulation for 8 weeks
Treatment Phase 2
Group 1 continues TSCS therapy and Group 2 switches to therapeutic TSCS for another 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Spinal Cord Neuromodulation (SCONE) for Transcutaneous Spinal Cord Stimulation (TSCS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
United States Department of Defense
Collaborator
Rivne Regional War Veterans Hospital, Spinal Cord Injury Rehabilitation Center
Collaborator
Congressionally Directed Medical Research Programs
Collaborator